BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29303932)

  • 21. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study.
    Raspagliesi F; Maltese G; Bogani G; Fucà G; Lepori S; De Iaco P; Perrone M; Scambia G; Cormio G; Bogliolo S; Bergamini A; Bifulco G; Casali PG; Lorusso D
    Gynecol Oncol; 2017 Jan; 144(1):90-95. PubMed ID: 27817933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): pathology, follow-up and recurrence.
    Dall'Asta A; Gizzo S; Musarò A; Quaranta M; Noventa M; Migliavacca C; Sozzi G; Monica M; Mautone D; Berretta R
    Int J Clin Exp Pathol; 2014; 7(11):8136-42. PubMed ID: 25550862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of bone morphogenetic protein-2 expression in smooth muscle tumors of the uterine corpus and other uterine tissues.
    Fadare O; Renshaw IL; Liang SX
    Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):352-9. PubMed ID: 21285872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uterine smooth muscle tumors of uncertain malignant potential: diagnostic challenges and therapeutic dilemmas. Report of 2 cases and review of the literature.
    Vilos GA; Marks J; Ettler HC; Vilos AG; Prefontaine M; Abu-Rafea B
    J Minim Invasive Gynecol; 2012; 19(3):288-95. PubMed ID: 22546421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EMMPRIN (CD147) Expression in Smooth Muscle Tumors of the Uterus.
    Kefeli M; Yildiz L; Gun S; Ozen FZ; Karagoz F
    Int J Gynecol Pathol; 2016 Jan; 35(1):1-7. PubMed ID: 26352545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
    Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
    Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.
    Croce S; Ribeiro A; Brulard C; Noel JC; Amant F; Stoeckle E; Devouassoux-Shisheborah M; Floquet A; Arnould L; Guyon F; Mishellany F; Garbay D; Cuppens T; Zikan M; Leroux A; Frouin E; Duvillard P; Terrier P; Farre I; Valo I; MacGrogan GM; Chibon F
    Mod Pathol; 2015 Jul; 28(7):1001-10. PubMed ID: 25932961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma.
    Zhang Q; Ubago J; Li L; Guo H; Liu Y; Qiang W; Kim JJ; Kong B; Wei JJ
    Cancer; 2014 Oct; 120(20):3165-77. PubMed ID: 24986214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelioid smooth muscle tumors of the uterus do not express CD1a: a potential immunohistochemical adjunct in their distinction from uterine perivascular epithelioid cell tumors.
    Fadare O; Liang SX
    Ann Diagn Pathol; 2008 Dec; 12(6):401-5. PubMed ID: 18995203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uterine smooth muscle tumors of uncertain malignant potential: a case presentation.
    Gezginç K; Yazici F; Tavli L
    Int J Clin Oncol; 2011 Oct; 16(5):592-5. PubMed ID: 21225306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
    Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F
    Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study.
    Veras E; Malpica A; Deavers MT; Silva EG
    Int J Gynecol Pathol; 2009 Jul; 28(4):316-21. PubMed ID: 19483635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.
    Borella F; Cosma S; Ferraioli D; Ray-Coquard I; Chopin N; Meeus P; Cockenpot V; Valabrega G; Scotto G; Turinetto M; Biglia N; Fuso L; Mariani L; Franchi D; Vidal Urbinati AM; Pino I; Bertschy G; Preti M; Benedetto C; Castellano I; Cassoni P; Bertero L
    Ann Surg Oncol; 2022 Dec; 29(13):8302-8314. PubMed ID: 35976464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
    Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
    Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis.
    Guntupalli SR; Ramirez PT; Anderson ML; Milam MR; Bodurka DC; Malpica A
    Gynecol Oncol; 2009 Jun; 113(3):324-6. PubMed ID: 19342083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evaluation of the caveolin-1 and AT-rich interactive domain 1 alpha expressions in uterine smooth muscle tumors.
    Ayaz D; Diniz G; Kahraman DS; Sayhan S; Uncel M; Karadeniz T; Sanci M
    Indian J Pathol Microbiol; 2016; 59(3):301-4. PubMed ID: 27510664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Literature review of outcomes and prevalence and case report of leiomyosarcomas and non-typical uterine smooth muscle leiomyoma tumors treated with uterine artery embolization.
    Kainsbak J; Hansen ES; Dueholm M
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():130-7. PubMed ID: 26117442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior.
    Giuntoli RL; Gostout BS; DiMarco CS; Metzinger DS; Keeney GL
    J Reprod Med; 2007 Nov; 52(11):1001-10. PubMed ID: 18161397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].
    Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK
    Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.